Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemwall on Mevacor

This article was originally published in The Tan Sheet

Executive Summary

"I really don't want to read any more in 'The Tan Sheet' once a week about the 20-3 vote on the approvability question" regarding the proposed Rx-to-OTC switch of 20 mg Mevacor, J&J/Merck VP-Scientific & Regulatory Affairs Ed Hemwall quipped during the Consumer Healthcare Products Association's Regulatory & Scientific Conference in Washington, D.C. May 5. Hemwall spoke at the FDA advisory committee meeting on the switch application in January (1"The Tan Sheet" Jan. 17, 2005, p. 3). Despite the panel's recommendation against approval, the sponsor "made a lot of very good progress," Hemwall said. "We also had several 25-0 votes on major safety and efficacy issues," such as muscle and liver safety and drug interactions, he noted. "It [comes back to] understanding consumer behavior...that's the final piece of information that's going to be needed if a drug of this type is ever going to switch"...
Advertisement

Related Content

Mevacor OTC Panel Rejection Elicits Third Drug Class Talk
Mevacor OTC Panel Rejection Elicits Third Drug Class Talk

Topics

Advertisement
UsernamePublicRestriction

Register

PS098170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel